Bioorganic & medicinal chemistry letters
Design and validation of the first-in-class PROTACs for targeted degradation of the immune checkpoint LAG-3.
Nelson García Vázquez, Somaya A Abdel-Rahman, Hossam Nada, Moustafa Gabr
Published: 202510.1016/j.bmcl.2025.130428
Abstract
Lymphocyte activation gene-3 (LAG-3) is an inhibitory immune checkpoint receptor that plays a central role in T cell exhaustion and immune evasion in cancer. While monoclonal antibodies targeting LAG-3 have entered clinical development, small molecul…
Preview only. Read the full abstract at the source